An oral suspension, immediate-release form of budesonide is safer and more effective than placebo for children and adolescents with eosinophilic esophagitis (EoE), according to a pooled retrospective analysis. But the FDA recently called for additional studies before it would consider approval.
In the study, the results of which were presented at the 2021 meeting of the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition (NASPGHAN) (poster P271), investigators